Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Regeneron Pharmaceuticals rose $7.36 (2.2%) to $334.98 on heavy volume. Throughout the day, 1,527,731 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 890,300 shares. The stock ranged in a price between $326.70-$340.24 after having opened the day at $328.75 as compared to the previous trading day's close of $327.62. Other companies within the Drugs industry that increased today were: ACADIA Pharmaceuticals ( ACAD), up 17.3%, Isis Pharmaceuticals ( ISIS), up 15.5%, Idera Pharmaceuticals ( IDRA), up 15.4% and Revance Therapeutics ( RVNC), up 15.2%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $31.8 billion and is part of the health care sector. Shares are up 19.0% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and feeble growth in the company's earnings per share.

On the negative front, Aoxing Pharmaceutical Company ( AXN), down 16.7%, Tekmira Pharmaceuticals Corporation ( TKMR), down 6.4%, Skystar Bio-Pharmaceutical Company ( SKBI), down 6.3% and Progenics Pharmaceuticals ( PGNX), down 5.9% , were all laggards within the drugs industry with Allergan ( AGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump